Treatment of schizophrenia: A clinical and preclinical evaluation of neuroleptic drugs
- 31 December 1993
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 57 (1) , 1-78
- https://doi.org/10.1016/0163-7258(93)90036-d
Abstract
No abstract availableKeywords
This publication has 462 references indexed in Scilit:
- Metabolism of Clozapine† by NeutrophilsDrug Safety, 1992
- On the Possible Mechanisms and Predictability of Clozapine†-Induced AgranulocytosisDrug Safety, 1992
- Clinical Experience of Clozapine†-Induced Neutropenia in the UKDrug Safety, 1992
- HLA-Associations in Leponex®/Clozaril® (Clozapine)-Induced Granulocytopenia and AgranulocytosisDrug Safety, 1992
- No Direct Clinical Relevance of the Human Leucocyte Antigen (HLA) System in Clozapine†-Induced AgranulocytosisDrug Safety, 1992
- A Report of Clozapine† - Induced Agranulocytosis in the United StatesDrug Safety, 1992
- Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in ratsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1990
- Regional blockade by neuroleptic drugs ofin vivo 3H-spiperone binding in the rat brain. Relation to blockade of apomorphine induced hyperactivity and stereotypiesJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1981
- Differential effects of typical and atypical neuroleptics on alpha-noradrenergic and dopaminergic postsynaptic receptorsNeuropharmacology, 1979
- Drug-Induced AgranulocytosisDrugs, 1978